Niagen Bioscience, Inc. splits its revenue into 3 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Consumer Products at $97.7 million, 75% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
FY 2017
Dec 30, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
122
|
129
|
100
|
84
|
72
|
67
|
59
|
46
|
32
|
—
|
—
|
| Consumer Products |
97
+4.8%
share 79.6%
|
98
+27.2%
share 75.5%
|
77
+10.4%
share 77.1%
|
70
+15.7%
share 83.2%
|
60
+6.0%
share 83.4%
|
57
+20.4%
share 84.1%
|
47
share 79.5%
|
—
|
—
|
—
|
—
|
| Ingredients |
23
-18.4%
share 19.2%
|
29
+44.7%
share 22.2%
|
20
+77.9%
share 19.9%
|
11
+27.5%
share 13.3%
|
9
+17.9%
share 12.1%
|
7
-19.5%
share 11.0%
|
9
share 15.5%
|
—
|
—
|
—
|
—
|
| Analytical Reference Standards And Services |
1
-64.0%
share 0.9%
|
3
+2.2%
share 2.4%
|
3
+3.6%
share 3.0%
|
3
-9.3%
share 3.5%
|
3
-4.0%
share 4.4%
|
3
+12.4%
share 4.9%
|
3
share 5.0%
|
—
|
—
|
—
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- NAGE (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Los Angeles, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1386570
- Former names
- ChromaDex Corp. (until Mar 10, 2025); CODY RESOURCES, INC. (until Jun 24, 2008)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Source: SEC EDGAR filings. This is company-reported data, not investment advice.